David Kirn, 4D Molecular Therapeutics CEO

4D Mol­e­c­u­lar Ther­a­peu­tic­s' gene ther­a­py cuts Eylea use in wet AMD pa­tients, biotech di­vulges plans for piv­otal stud­ies

4D Mol­e­c­u­lar Ther­a­peu­tics said peo­ple with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) who re­ceived the com­pa­ny’s gene ther­a­py as part of a clin­i­cal tri­al need­ed few­er in­jec­tions of Eylea, a sta­ple treat­ment for the eye dis­ease.

In the Phase II PRISM study, 51 pa­tients with wet AMD re­ceived ei­ther 4D’s gene ther­a­py or their usu­al in­jec­tions of Eylea, a block­buster med­i­cine mar­ket­ed by Re­gen­eron. Over 24 weeks, 63% of the pa­tients who re­ceived a high dose of the gene ther­a­py, dubbed 4D-150, and 50% of those who re­ceived the low dose did not need sup­ple­men­tal Eylea in­jec­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.